Jerzewski K, Ruel M, Voisine P, Le May MR, Kulik A. Does high- density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial. J Cardiothorac Surg. 2013;8:172. doi: 10.1186/1749-8090-8-172. 167. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120 122. doi: 10.1016/j.amjcard.2004.08.076. 168. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97:27C 31C. doi: 10.1016/j.amjcard.2005.12.007. 169. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein choles- terol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213 219. 170. Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocar- dial infarction and stroke: new data from the Prospective Cardiovascular M nster (PROCAM) study. Eur J Clin Invest. 2007;37:925 932. doi: 10.1111/j.1365-2362.2007.01888.x. 171. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143 3421. 172. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413 1419. 173. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316 322. doi: 10.1016/j.jacc.2008.10.024. 174. 